MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517048731 A) filed by Peptomyc, S. L.; Fundacio Privada Institut D'Investigacio Oncologica De Vall Hebron; and Institucio Catalana De Recerca I Estudis Avancats, Barcelona, Spain, on May 20, for 'combination therapy for the treatment of cancer.'
Inventor(s) include Soucek, Laura; Giuntini, Fabio; and Masso-Valles, Daniel.
The application for the patent was published on June 6, under issue no. 23/2025.
According to the abstract released by the Intellectual Property India: "The invention relates to a combination of a PARP inhibitor with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide and a cell capable of secreting the polypeptide or the conjugate. The invention also relates to pharmaceutical compositions containing the combination of the invention and to their medical uses, particularly their uses in the treatment of cancer."
The patent application was internationally filed on Oct. 24, 2023, under International application No.PCT/EP2023/079593.
Disclaimer: Curated by HT Syndication.
